UBS Group restated their neutral rating on shares of GlaxoSmithKline (LON:GSK) in a report issued on Friday, ThisIsMoney.Co.Uk reports.
Other equities analysts have also recently issued reports about the stock. HSBC set a €11.20 ($13.02) price objective on shares of ThyssenKrupp and gave the stock a neutral rating in a research report on Tuesday, July 16th. Kepler Capital Markets lifted their price objective on shares of GlaxoSmithKline from GBX 1,440 ($18.82) to GBX 1,540 ($20.12) and gave the stock a hold rating in a research report on Tuesday, June 11th. Liberum Capital reiterated a hold rating on shares of Daily Mail and General Trust P L C in a research report on Tuesday, July 2nd. Goldman Sachs Group reiterated a buy rating and set a $70.00 price objective on shares of Total in a research report on Monday, July 15th. Finally, Jefferies Financial Group reiterated a buy rating and set a C$15.00 price objective on shares of Aphria in a research report on Friday, May 24th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Hold and an average target price of GBX 1,536.87 ($20.08).
GlaxoSmithKline stock opened at GBX 1,654.60 ($21.62) on Friday. The company has a debt-to-equity ratio of 942.07, a quick ratio of 0.45 and a current ratio of 0.72. The firm has a market capitalization of $82.53 billion and a price-to-earnings ratio of 21.08. GlaxoSmithKline has a 1 year low of GBX 1,408.80 ($18.41) and a 1 year high of GBX 1,658 ($21.66). The business has a 50 day simple moving average of GBX 1,603.27.
The company also recently disclosed a dividend, which was paid on Thursday, July 11th. Shareholders of record on Thursday, May 16th were given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.22%. The ex-dividend date of this dividend was Thursday, May 16th. GlaxoSmithKline’s payout ratio is 0.97%.
In related news, insider Manvinder Singh Banga purchased 458 shares of the stock in a transaction dated Wednesday, May 1st. The shares were acquired at an average cost of GBX 1,568 ($20.49) per share, for a total transaction of £7,181.44 ($9,383.82). Over the last 90 days, insiders have bought 482 shares of company stock worth $755,935.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: What can cause a stock to outperform?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.